Telix Pharmaceuticals Limited is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in North Melbourne, AU. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $804 million and a loss of $7 million (its filed statements).
Product businessPharmaceutical PreparationsNorth Melbourne, AUfilings since 20247 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.5 out of ten, 7 of 9 metrics filed and 2 estimated: past 7.6 out of ten, present 6.8 out of ten, future 5.2 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2024. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 8.7 out of ten. +55.3% a year over 3 filed years; profitable in 2 of 3. 87th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 4.3 out of ten. Share count grew 2.8% a year. 0% of cash flow returned. Insiders: 0 sales, 3 purchases. 43rd percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 6.8 out of ten. ROE -2%: lost 2¢ per shareholder dollar. Leverage 64%: owes 64¢ per asset dollar. 68th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 7.9 out of ten. top 21% of 314 in its family; net margin -0.9%. 79th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 371 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 3.2 out of ten. bottom 32% of 272 in its family for room to expand. 32nd percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 7.9 out of ten. top 21% of 307 in its family for growth drivers. 79th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 5.3 out of ten. CrossAssetData estimate 5.3/10, confidence 20 of 100 (family median). 50th percentile among 235 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
The filing record
Newest annual report: Form 20-F filed 2026-02-20 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 6-K, 2026-09-30. Filings on record since 2024. Read from EDGAR 2026-10-12.
Who runs it
Behrenbruch, Christian (MD & Group CEO); Smith, Darren Charlton (Group Chief Financial Officer); Patti, Darren Joel (Group Chief Operating Officer); Cade, David Norman (Group Chief Medical Officer); Gill, David N (director); Jellison, William R (director); Rivas, Maria (director); Nelson, Mark Alexander (director); Mcdonald, Marie Elizabeth (director); Skinner, Jann Elizabeth (director). 10 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.